Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (14522)	2/10/1998 10:22:00 AM
From: Hippieslayer	Read Replies (1) \| Respond to of 32384

I remember reading the article since I get the La times. But most people probably didn't see which is a good thing. Most guys, at least, just look at the sports page to check the box scores and to check out the latest dancers at the local MEN'S entertainment places. Otherwise, the LA times is a horrible paper. I've also noticed that MM hasn't been on CNBC lately. HAve they wised up?

To: Henry Niman who wrote (14522)	2/10/1998 12:11:00 PM
From: AJAG	Respond to of 32384

CHIR Betaseron News- Excuse me for interrupting, Henry. As the reigning biotech expert on our thread, what do you think of the Betaseron trial news released this morning by Schering's Berlex unit? See my note under Chiron board.

To: Henry Niman who wrote (14522)	2/10/1998 6:59:00 PM
From: Hippieslayer	Read Replies (2) \| Respond to of 32384

Henry, There are a couple things that I'd like your thoughts on: 1.''Because there are many more KS patients with no available alternative oral treatments to chemotherapy than there are patients with acute promyelocytic leukemia (APL), we will restructure our more slowly accruing APL program by terminating one of our ongoing Phase III studies, and we will channel our resources into the KS indication with a goal of completing an NDA filing in 1999, our targeted timetable,'' Mr. Robinson said. Huh? They are dropping a PIII study for APL due to a problem of getting patients. What's up with this? 2. In the studies, Panretin Capsules were administered once daily at doses increasing from 60 mg/m2 to 100 mg/m2/day One pill a day sounds good. What is the protocal now with patients who have KS? Ie how are they treated? 3.Drug side effects were generally manageable, with some patients requiring dose reductions with headache, dry skin, rash, alopecia, peeling/flaking, and hyperlipidemia as the most common events. What are the side effects of existing drugs used to treat this disease? 4. Phase II trials are ongoing in breast, ovarian, pediatric cancers, and bronchial metaplasia Do you know where these trial stand? I would think that if Panretin has the same success with just one of the specific cancers above--especially breast cancer--as it has with KS, were looking at a $100 dollar stock IMHO. 5.Two pivotal Phase III trials of Panretin(TM) Gel for topical treatment of KS have been completed to support an NDA filing in the first quarter of 1998. The trials showed response rates of 42 and 35 percent respectively at 16-week assessments, and up to 48 percent response with continued treatment beyond 16 weeks. What exactly does the "up to 48 percent response with continued treatement beyond 16 weeks" mean? Is that suppose to mean that everyone still showed progress of up to 48 percent after the 16 week trial? The statistic that was thrown in doesn't quite explain itself. Thanks